Home › Funds › FARALLON CAPITAL MANAGEMENT, L.L.C. › ENTA

FARALLON CAPITAL MANAGEMENT, L.L.C. position in ENTA

ENANTA PHARMACEUTICALS INC COM · Health Care

FARALLON CAPITAL MANAGEMENT, L.L.C. reported holding 2,418,202 shares of ENTA (ENANTA PHARMACEUTICALS INC COM) in its Q2 2026 13F filing — a position valued at US$35.3M, representing 0.16% of its reported portfolio and ranking #42 among its reported holdings. FARALLON CAPITAL MANAGEMENT, L.L.C. has disclosed ENTA holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)2.42M sh
Reported value held$35.26M
Portfolio Weight0.16%
First reportedQ3 2023
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How FARALLON CAPITAL MANAGEMENT, L.L.C.'s ENTA position evolved

FARALLON CAPITAL MANAGEMENT, L.L.C. first disclosed a stake in ENTA in Q3 2023 at 1,875,000 shares (US$20.9M). The position peaked in Q4 2025 at 2,772,262 shares, worth US$43.7M. Across 12 filings, FARALLON CAPITAL MANAGEMENT, L.L.C. increased the stake 6 time(s), trimmed it 1 time(s) and left it unchanged 4 time(s). The most recent filing (Q2 2026) shows 2,418,202 shares valued at US$35.3M — a reduction of -453,660 shares quarter over quarter.. Notable position changes include a 31% increase in Q4 2025 (shares fell 20% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 1.88M $20.94M New
Q4 2023 2.02M $19.06M Add
Q1 2024 2.10M $36.58M Add
Q2 2024 2.10M $27.17M Hold
Q3 2024 2.11M $21.84M Add
Q4 2024 2.11M $12.12M Hold
Q1 2025 2.12M $11.71M Add
Q2 2025 2.12M $16.04M Hold
Q3 2025 2.12M $25.40M Hold
Q4 2025 2.77M $43.72M Add
Q1 2026 2.87M $36.27M Add
Q2 2026 2.42M $35.26M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ENTA and 13F data

ENTA (ENANTA PHARMACEUTICALS INC COM) is a Health Care company. 28 other funds we track also report a position in ENTA — the largest reported positions include Krensavage Asset Management, LLC (US$41.8M), Farallon Capital Management (US$35.3M), ADAR1 Capital Management, LLC (US$19.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ENTA

All ENTA fund holders →

FAQ

How long has FARALLON CAPITAL MANAGEMENT, L.L.C. held ENTA?

FARALLON CAPITAL MANAGEMENT, L.L.C. has disclosed ENTA holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is FARALLON CAPITAL MANAGEMENT, L.L.C.'s current position in ENTA?

As of Q2 2026, FARALLON CAPITAL MANAGEMENT, L.L.C. holds 2.42M shares of ENTA (ENANTA PHARMACEUTICALS INC COM), valued at $35.26M, representing 0.16% of its reported portfolio and ranking #42.

Has FARALLON CAPITAL MANAGEMENT, L.L.C. been buying or selling ENTA?

In the latest 13F filing (Q2 2026), FARALLON CAPITAL MANAGEMENT, L.L.C. reduced its position in ENTA. The position peaked in Q4 2025 at 2.77M shares.

Which other funds hold ENTA?

Other major institutional holders of ENTA include Krensavage Asset Management, LLC, Farallon Capital Management, ADAR1 Capital Management, LLC, among 28 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.